The Oral GLP-1 Race in 2026: What the Wegovy Pill, Foundayo, and the NICE July Appraisal Mean for UK Research Procurement

Key takeaways

• The MHRA approved the Wegovy pill (oral semaglutide 25 mg) on 11 June 2026; private prescribing in the UK began shortly thereafter, but NHS commissioning awaits a separate NICE appraisal.
• The FDA approved Foundayo (orforglipron, Eli Lilly) on 1 April 2026 — the first non-peptide, small-molecule oral GLP-1 receptor agonist — under the National Priority Voucher Programme.
• According to The Pharmaceutical Journal, a NICE committee is due to meet in July 2026 to discuss NHS use of orforglipron in England and Wales, though Foundayo does not yet hold a UK marketing authorisation.
• The two agents differ substantially in molecular architecture, dosing flexibility, and manufacturing complexity — differences with direct implications for supply-chain resilience and research compound sourcing.
• The MHRA issued a drug-safety alert on GLP-1 pancreatitis risk in January 2026, a signal that post-market surveillance is actively shaping labelling across the class.

Background: a market that has outgrown injectable-only supply

The UK market for GLP-1 weight-loss medicines has expanded rapidly. The Pharmaceutical Journal reports that more than four million items of tirzepatide and semaglutide were dispensed on the NHS in England in 2025/2026, with approximately 2.5 million people per month accessing GLP-1 therapies privately by the end of 2025. A YouGov poll commissioned by the National Pharmacy Association estimated that 3.3 million UK adults are expected to use weight-loss injections in 2026. Supply shortages of both Wegovy (injectable semaglutide) and Mounjaro (tirzepatide) have delayed treatment at scale since their NHS launches, underscoring structural demand that the injectable format alone has struggled to meet.

Oral formulations entered this context as a potential supply-chain release valve as well as a clinical alternative for patients who are needle-averse or unable to adhere to injectable regimens.

Two distinct oral approaches: peptide versus small molecule

The two oral GLP-1 agents now on or approaching the UK market use fundamentally different chemistry — a distinction that matters for procurement, cold-chain logistics, and longer-term research access.

Oral semaglutide (Wegovy pill, Novo Nordisk) is a peptide molecule co-formulated with the absorption enhancer salcaprozate sodium (SNAC). The SNAC co-formulation enables some intestinal absorption of semaglutide, but strict conditions apply: Patient Care Online notes that only approximately 0.4% to 1% of each oral semaglutide dose is absorbed under optimal conditions, and the drug must be taken on an empty stomach with no more than 4 oz of plain water, followed by a mandatory 30-minute fast. As a peptide, the active moiety requires the same cold-chain handling as the injectable form at the manufacturing and distribution level, though end-users receive a tablet. The MHRA approved the Wegovy pill on 11 June 2026, making it the first GLP-1 weight-loss tablet licensed in the UK; Novo Nordisk indicated it expected availability via private providers within weeks of that decision.

In the OASIS 4 trial, the Wegovy pill produced an average weight loss of 13.6% at 64 weeks, with a 16.6% average among participants who reached the full 25 mg dose and remained on treatment, compared with 2.2% on placebo, according to Second Nature.

Orforglipron (Foundayo, Eli Lilly) takes a structurally different route. Patient Care Online explains that orforglipron's non-peptide, small-molecule structure enables oral bioavailability without absorption enhancers, circumventing the pharmacokinetic limitation that demands fasting with peptide-based oral GLP-1 agents. It can therefore be taken at any time of day with or without food or drink. The FDA approved Foundayo on 1 April 2026 for adults with obesity or overweight with at least one weight-related comorbidity. In the ATTAIN-1 trial, adults with obesity achieved an average weight loss of 12.4% with the highest 36 mg dose at 72 weeks, according to Healio. Approximately 54.6% of participants in the 36 mg group achieved ≥10% body weight reduction, according to Patient Care Online.

Because orforglipron is a small molecule, NowPatient notes that it does not require cold-chain storage or distribution infrastructure, reducing logistical costs throughout the supply chain. This manufacturing distinction is meaningful for research-grade sourcing: small molecules are generally simpler and cheaper to produce at scale, and future generic or research-grade access is structurally more straightforward than for peptide compounds. A Medscape report from the ADA 2026 Scientific Sessions cited an investigator's observation that once orforglipron goes off patent, it will be easy to produce and relatively inexpensive — a longer-term dynamic that could reshape the research-use market.

Phase 3 evidence: maintenance and head-to-head data

Beyond the pivotal obesity trials, the ATTAIN-MAINTAIN study — a phase 3b randomised controlled trial published in Nature Medicine in May 2026 — addressed a critical clinical question: can switching from an injectable GLP-1 to an oral pill maintain weight already lost? Weill Cornell Medicine reports that patients who switched from semaglutide to orforglipron maintained a mean 79.3% of their body weight reduction, compared with 37.6% in the placebo arm. Those switching from tirzepatide maintained 74.7%, versus 49.2% for placebo. The difference between the semaglutide and tirzepatide transition groups is mechanistically consistent: tirzepatide's additional GIP receptor activity produces greater initial weight loss, which appears harder to sustain when switching to a single-receptor agent.

In type 2 diabetes, ACHIEVE-3 — published in The Lancet in March 2026 — provided the first head-to-head comparison between two oral GLP-1 agents. AJMC reports that orforglipron delivered superior blood-sugar control and weight loss compared with oral semaglutide (Rybelsus) in that trial. However, Medscape notes that orforglipron had a somewhat worse tolerability profile than semaglutide in those comparisons, a point likely to feature in NHS cost-effectiveness modelling.

UK regulatory and access timeline for procurement planning

The two agents are at different stages in the UK regulatory pathway:

Oral semaglutide (Wegovy pill): MHRA-approved as of 11 June 2026 and available via private prescription. Second Nature quotes private pricing from approximately £149 per month. NICE has not yet appraised it for weight management, so there is no NHS funding route and no confirmed timeline for one. A NICE appraisal would need to be initiated before any NHS commissioning decision could be made.

Orforglipron (Foundayo): Not yet approved in the UK. Walton Surgery reports that the FDA approved it on 1 April 2026 under the brand name Foundayo, but that no UK marketing authorisation exists as of mid-2026. Eli Lilly is preparing its MHRA application; through the MHRA's International Recognition Procedure — which draws on the FDA review — a UK licence could arrive in late 2026 if the submission proceeds on schedule. Private prescribing would likely follow, with NHS access dependent on a NICE appraisal that NowPatient suggests is unlikely to conclude before 2027 at the earliest. Separately, The Pharmaceutical Journal notes that a NICE committee is due to meet this month — July 2026 — to discuss NHS use of orforglipron, indicating that parallel preparatory work is already under way.

It is worth noting that as of mid-2026 the UK private market for orforglipron is not legally open: any website or service claiming to prescribe or supply orforglipron in the UK prior to MHRA authorisation is operating outside the regulatory framework, according to NowPatient.

Safety signals and MHRA surveillance

On 29 January 2026, The Pharmaceutical Journal reports that the MHRA updated product information for GLP-1 agents and issued a drug-safety alert highlighting that acute pancreatitis is a known but infrequent side effect that can be fatal, urging clinicians and patients to be alert to severe, persistent abdominal pain that may radiate to the back. Post-marketing data show 1,176 cases of acute and chronic pancreatitis following tirzepatide use reported between January 2023 and June 2026, 18 of which had a fatal outcome.

For orforglipron, the safety profile differs in one relevant respect. A review published in PMC in 2026 (Orforglipron: A Comprehensive Review, PMC) notes that in contrast to peptide GLP-1 agents, orforglipron has not shown clinical signals of pancreatitis, retinal detachment, or ischaemic optic neuropathy in trial data to date, though long-term post-market surveillance will be required to assess rarer events.

Implications for research procurement

For UK laboratory procurement teams, several practical considerations follow from this landscape:

1. Research-grade sourcing of oral semaglutide is subject to the same peptide cold-chain and purity standards as injectable semaglutide. Certificates of Analysis should confirm HPLC purity, peptide content, and salt form, given documented concerns about unapproved salt forms in compounded GLP-1 products.

2. Orforglipron as a small-molecule research compound is not yet available via UK commercial or clinical channels. Procurement of reference standards or research quantities for pharmacological studies must go through approved chemical suppliers with appropriate documentation; no clinical-grade supply pathway currently exists in the UK.

3. NICE QALY threshold changes from April 2026 — raising the cost-effectiveness ceiling from £20,000–£30,000 to £25,000–£35,000 per quality-adjusted life year, as NHS Confederation reports — may improve the probability of a positive NICE recommendation for both agents, but NHS commissioning timelines for GLP-1 obesity therapies remain slow by design, with tirzepatide's NHS rollout projected to take up to 12 years to reach the full eligible population.

4. Injectable versus oral supply dynamics will converge over the next 12–18 months. Procurement contracts that currently specify injectable semaglutide or tirzepatide for research use may need to be reviewed as oral equivalents receive UK authorisation and begin to appear in clinical study designs.

This article is an informational briefing for research and procurement professionals. It does not constitute clinical, legal, or regulatory advice. Product availability and regulatory status should be confirmed with the relevant manufacturer and regulatory authority before procurement decisions are made.